Stroobant, Emily E.
Sreeram, Aravind
Strong, Vivian E.
Funding for this research was provided by:
NIH (P30 CA008748)
Article History
Received: 17 September 2024
Accepted: 19 September 2024
First Online: 10 October 2024
Disclosures
: Vivian E. Strong reports a one-time speaking honorarium from AstraZeneca and a one-time consultation for Regeneron. Aravind Sreeram and Emily E. Stroobant report no relationships with outside entities.